Attention COVID-19 Survivors: You beat it. Now you could help fight it.
Visit TheFightIsInUs.org now to learn more about the urgent need for you to donate your strength — donate your plasma.
Close

This Site Is Intended for U.S. Healthcare Professionals Only

Prescribing Information Indications and
Important Safety Information
  • HOME
  • About Albumin
    • USES OF ALBUMIN
    • SAFETY Profile
  • Portfolio
    • flexbumin 25%
    • flexbumin 5%
  • Benefits of the Bag
    • SAFETY Features
    • EFFICIENCY Features
    • SUSTAINABILITY Features
  • Ordering
    • CONTACT INFO

Request a sample GALAXY® container

Please complete the form below to request your sample of the FLEXBUMIN® Galaxy container.

*Denotes Mandatory Field.

We respect your privacy. By submitting this form, I understand that the information I have provided will be used by Shire and its contracted third parties to contact me by mail, email, and phone with helpful information on Shire treatments and indicated conditions. Shire will not sell or transfer my name or contact information to any third party for their marketing use.

If you ever decide that you do not wish to receive this information from us, contact us at: Consumer Relations, Shire, 1200 Lakeside Dr. Bannockburn, IL 60015 or at +1-224-940-2000 . This site does not seek to collect personal information from children under the age of 13 and will not retain this information if aware of its receipt. The privacy notice in its entirety can be accessed here

Click here for sample:*

BACK

Important Safety Information

Please read below for Indications and Detailed Important Safety Information for FLEXBUMIN 25% AND 5%.

Indications and Important Safety Information for FLEXBUMIN 5% [Albumin (Human)], USP, 5% and FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solutions

Indications and Limitation of Use for FLEXBUMIN 5% and 25%

FLEXBUMIN 5% and 25% are indicated for hypovolemia, hypoalbuminemia (burns), and cardiopulmonary bypass surgery. Albumin is not indicated as an intravenous nutrient.

FLEXBUMIN 25% is also indicated for hypoalbuminemia due to adult respiratory distress syndrome (ARDS) and nephrosis and for hemolytic disease of the newborn (HDN).


IMPORTANT SAFETY INFORMATION

Contraindications

  • History of hypersensitivity reaction to albumin preparations or to any of the excipients (N-acetyltryptophan and sodium caprylate). Reactions have included anaphylactic shock, anaphylactic reaction, or hypersensitivity/allergic reactions.

  • Severe anemia or cardiac failure with normal or increased intravascular volume.

Warnings and Precautions

Hypersensitivity Reactions:

 have been observed (including anaphylactic reactions). If hypersensitivity reaction is suspected, discontinue administration immediately and implement appropriate standard medical treatment.

Hypervolemia/Hemodilution:

 Under conditions where hypervolemia and/or hemodilution may occur, adjust the dose and rate of infusion to the patient’s volume status. When administering large volumes, monitor hemodynamic parameters. Ensure adequate substitution of other blood constituents and monitor electrolyte balance. Discontinue administration at the first clinical signs of cardiovascular overload.

Hemodynamics:

 Closely monitor hemodynamic parameters after administration for evidence of cardiac or respiratory failure, renal failure or increasing intracranial pressure.

Blood Pressure:

 Monitor blood pressure in trauma patients and postoperative surgery patients in order to detect re-bleeding secondary to clot disruption.

Hemolysis:

 Do not dilute with Sterile Water for Injection, as there is potential risk of fatal hemolysis and acute renal failure in recipients.

Transmission of Infectious Agents:

 Because FLEXBUMIN 5% is made from human plasma it may carry a risk of transmitting infectious agents (e.g., viruses, other pathogens). No cases of transmission of viral diseases, Creutzfeldt-Jakob disease (CJD) or variant Creutzfeldt-Jakob disease (vCJD) have ever been identified.

Adverse Reactions

The most serious adverse reactions are hypersensitivity reaction (including anaphylactic reaction) and pulmonary edema.

Administration Caution

Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete.

For full details please see the Prescribing Information for FLEXBUMIN 5% and FLEXBUMIN 25%.

© 2018 Shire US Inc., Lexington, MA 02421. All rights reserved. 1-800-828-2088

SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates.

BUMINATE and FLEXBUMIN are registered trademarks of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

Baxter and Galaxy are registered trademarks of Baxter International Inc.

S44698 04/19

  • Terms & Conditions
  • Shire.com
  • Privacy Notice
  • Sitemap
  • Contact Us
Shire logo